GlassScriptPhysician profile
Ilya Schwartzman
NPI 1144252552
$1,629.84
in general payments reported to CMS, 2019-2025
23 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $308 · 2021: $13.67 · 2022: $199 · 2023: $269 · 2024: $282 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.54 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $256.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $180.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $145.43 | 2019-2025 | Wegovy, Ozempic |
| Abbvie INC. | $102.14 | 2023-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.72 | 2022-2023 | Xifaxan |
| Welch Allyn | $96.25 | 2019 | |
| Abbott Laboratories | $70.03 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2019-2022 | |
| Exact Sciences Corporation | $39.45 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $36.26 | 2023 | Quviviq |
| Lundbeck LLC | $33.15 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $30.40 | 2019-2023 | |
| Edwards Lifesciences Corporation | $28.93 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Adlon Therapeutics L.P. | $26.58 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.82 | 2022 | |
| Axsome Therapeutics, INC. | $20.09 | 2024 | Auvelity |
| Amarin Pharma, INC. | $15.12 | 2020 | |
| Almatica Pharma LLC | $14.80 | 2023 | Loreev Xr |
| Gilead Sciences, INC. | $14.55 | 2019 | |
| Verona Pharma, INC. | $13.98 | 2025 | Ohtuvayre |
| Mycovia Pharmaceuticals, INC. | $13.19 | 2023 | Vivjoa |
| Pfizer INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Schwartzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.